Skyrizi (risankizumab) is an interleukin-23 antagonist. Interleukin-23 triggers an inflammatory response in the skin.
Skyrizi injection is a prescription medicine used to treat moderate to severe plaque psoriasis in adults who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
It is not known if Skyrizi is safe and effective in children under 18 years of age.
